Yazar "Goksel, Tuncay" seçeneğine göre listele
Listeleniyor 1 - 20 / 49
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe A novel approach utilizing rapid thin-film microextraction method for salivary metabolomics studies in lung cancer diagnosis(Elsevier, 2024) Pelit, Fusun; Erbas, Ilknur; Ozupek, Nazli Mert; Gul, Merve; Sakrak, Esra; Ocakoglu, Kasim; Goksel, Ozlem; Pelit, Levent; Goksel, TuncayThis study investigated the potential of targeted salivary metabolomics as a convenient diagnostic tool for lung cancer (LC), utilizing a rapid TFME-based method. It specifically examines TFME blades modified with SiO2 nanoparticles, which were produced using a custom-made coating system. Validation of the metabolite biomarker analysis was performed by these blades using liquid chromatography-tandem mass spectroscopy (LCMS/MS). The extraction efficiencies of SiO2 nanoparticle/polyacrylonitrile (PAN) composite-coated blades were compared for 18 metabolites. Response surface methodology (RSM) was used to optimize the analysis conditions. Linear calibration plots were obtained for all metabolites at concentrations between 0.025 to 4.0 mu g/mL in the presence of internal standard, with correlation coefficients (R-2) ranging from 0.9975 to 0.9841. The limit of detection (LOD) and limit of quantitation (LOQ) were in the range of 0.014 to 0.97 mu g mL(-1) and 0.046 to 3.20 mu gmL(-1), respectively. The %RSD values for all analytes were within the acceptable range (less than 20 %) for the proposed method. The method was applied to the saliva samples of 40 patients with LC and 38 healthy controls. The efficacy of metabolites for LC diagnosis was determined by in silico methods and the results reveal that phenylalanine and purine metabolism metabolites (e.g., hypoxanthine) are of great importance for LC diagnosis. Furthermore, potentially significant biomarker analysis results from the ROC curve data reveal that proline, hypoxanthine, and phenylalanine were identified as potential biomarkers for LC diagnosis.Öğe Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries(Bmc, 2018) Rich, Anna; Baldwin, David; Alfageme, Inmaculada; Beckett, Paul; Berghmans, Thierry; Brincat, Stephen; Burghuber, Otto; Corlateanu, Alexandru; Cufer, Tanja; Damhuis, Ronald; Danila, Edvardas; Domagala-Kulawik, Joanna; Elia, Stefano; Gaga, Mina; Goksel, Tuncay; Grigoriu, Bogdan; Hillerdal, Gunnar; Huber, Rudolf Maria; Jakobsen, Erik; Jonsson, Steinn; Jovanovic, Dragana; Kavcova, Elena; Konsoulova, Assia; Laisaar, Tanel; Makitaro, Riitta; Mehic, Bakir; Milroy, Robert; Moldvay, Judit; Morgan, Ross; Nanushi, Milda; Paesmans, Marianne; Putora, Paul Martin; Samarzija, Miroslav; Scherpereel, Arnaud; Schlesser, Marc; Sculier, Jean-Paul; Skrickova, Jana; Sotto-Mayor, Renato; Strand, Trond-Eirik; Van Schil, Paul; Blum, Torsten-GerrietBackgroundA minority of European countries have participated in international comparisons with high level data on lung cancer. However, the nature and extent of data collection across the continent is simply unknown, and without accurate data collection it is not possible to compare practice and set benchmarks to which lung cancer services can aspire.MethodsUsing an established network of lung cancer specialists in 37 European countries, a survey was distributed in December 2014. The results relate to current practice in each country at the time, early 2015. The results were compiled and then verified with co-authors over the following months.ResultsThirty-five completed surveys were received which describe a range of current practice for lung cancer data collection. Thirty countries have data collection at the national level, but this is not so in Albania, Bosnia-Herzegovina, Italy, Spain and Switzerland. Data collection varied from paper records with no survival analysis, to well-established electronic databases with links to census data and survival analyses.ConclusionUsing a network of committed clinicians, we have gathered validated comparative data reporting an observed difference in data collection mechanisms across Europe. We have identified the need to develop a well-designed dataset, whilst acknowledging what is feasible within each country, and aspiring to collect high quality data for clinical research.Öğe Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial(Amer Soc Clinical Oncology, 2012) Ramlau, Rodryg; Gorbunova, Vera; Ciuleanu, Tudor Eliade; Novello, Silvia; Ozguroglu, Mustafa; Goksel, Tuncay; Baldotto, Clarissa; Bennouna, Jaafar; Shepherd, Frances A.; Le-Guennec, Solenn; Rey, Augustin; Miller, Vincent; Thatcher, Nicholas; Scagliotti, GiorgioPurpose To compare the efficacy of aflibercept (ziv-aflibercept), a recombinant human fusion protein targeting the vascular endothelial growth factor (VEGF) pathway, with or without docetaxel in platinum-pretreated patients with advanced or metastatic nonsquamous non-small-cell lung cancer. Patients and Methods In this international, double-blind, placebo-controlled phase III trial, 913 patients were randomly assigned to (ziv-)aflibercept 6 mg/kg intravenous (IV; n = 456) or IV placebo (n = 457), both administered every 3 weeks and in combination with docetaxel 75 mg/m(2). The primary end point was overall survival (OS). Other efficacy outcomes, safety, and immunogenicity were also assessed. Results Patient characteristics were balanced between arms; 12.3% of patients had received prior bevacizumab. (Ziv-)Aflibercept did not improve OS (hazard ratio [HR], 1.01; 95% CI, 0.87 to 1.17; stratified log-rank P = .90). The median OS was 10.1 months (95% CI, 9.2 to 11.6 months) for (ziv-) aflibercept and 10.4 months (95% CI, 9.2 to 11.9 months) for placebo. In exploratory analyses, median progression-free survival was 5.2 months (95% CI, 4.4 to 5.6 months) for (ziv-) aflibercept versus 4.1 months (95% CI, 3.5 to 4.3 months) for placebo (HR, 0.82; 95% CI, 0.72 to 0.94; P = .0035); overall response rate was 23.3% of evaluable patients (95% CI, 19.1% to 27.4%) in the (ziv-) aflibercept arm versus 8.9% (95% CI, 6.1% to 11.6%; P < .001) in the placebo arm. Grade >= 3 adverse events occurring more frequently in the (ziv-) aflibercept arm versus the placebo arm were neutropenia (28.0% v 21.1%, respectively), fatigue (11.1% v 4.2%, respectively), stomatitis (8.8% v 0.7%, respectively), and hypertension (7.3% v 0.9%, respectively). Conclusion The addition of (ziv-) aflibercept to standard docetaxel therapy did not improve OS. In exploratory analyses, secondary efficacy end points did seem to be improved in the (ziv-) aflibercept arm. The study regimen was associated with increased toxicities, consistent with known anti-VEGF and chemotherapy-induced events. J Clin Oncol 30:3640-3647. (C) 2012 by American Society of Clinical OncologyÖğe AFLIBERCEPT IN COMBINATION WITH DOCETAXEL FOR SECOND-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC): FINAL RESULTS OF A MULTINATIONAL PLACEBO-CONTROLLED PHASE III TRIAL (EFC10261-VITAL)(Lippincott Williams & Wilkins, 2011) Novello, Silvia; Ramlau, Rodryg; Gorbunova, Vera A.; Ciuleanu, Tudor E.; Ozguroglu, Mustafa; Goksel, Tuncay; Baldotto, Clarissa; Bennouna, Jaafar; Shepherd, Frances A.; Scagliotti, GiorgioÖğe Approach to hypersensitivity reactions to chemotherapeutics in patients with lung cancer(European Respiratory Soc Journals Ltd, 2013) Goksel, Ozlem; Goksel, Tuncay; Cok, Gursel; Karakus, Haydar; Erdinc, MunevverÖğe The Assessment of the Effect of Changes in Lung Cancer Follow-up Period on the Quality of Life Using EQ-5D Questionnaire and Follow Data (AKAYAK-1 Multicenter Project)(Akad Doktorlar Yayinevi, 2018) Erbaycu, Ahmet E.; Goksel, Tuncay; Eser, Erhan; Gursul, Kader K.; Basarik, Burcu; Oz, Aysen; Celik, Pinar; Ediz, Ebru C.; Hatipoglu, Osman; Yayla, Bedriye A.; Baser, Sevin; Baydur, HakanThe EURO-QOL (EQ-5D), a generic quality of life measure, is a self-report scale. The aim was to study the reliability, validity and feasibility of the Turkish version of the EQ-5D as an instrument to evaluate quality of life in lung cancer patients in Turkish society. A prospective cohort study carried out within the framework of the multicenter Lung Cancer Association Project which was conducted in collaboration with Turkish Thoracic Society, Lung and Pleural Malignancies working group and Health and Quality of Life Society. A total of 266 patients were included in the study with a mean age of 61.3 years. 75,9% of the patients had chemotherapy alone; 9% received sequential chemotherapy and radiotherapy, 8,6% were given concurrent chemotherapy and radiotherapy, and 6,4% of them received radical radiotherapy alone. EQ-5D score measures at the moment of diagnosis were found to be moderately reliable while measures at the 3rd chemotherapy cycle, 5th chemotherapy cycle and after the radiotherapy were highly reliable. The items of the EQ-5D were found to be consistent among themselves. EQ-5D Visual Analogue Scale scores at diagnosis, the 3rd cycle, the 5th cycle and following radiotherapy were assessed to be correlated with each other. EQ-5D scale was found to be valid as it meets the conditions of 6 fit indices in our study design. The psychometric properties of the Turkish version of the EQ-5D questionnaire is a valid and reliable scale for patients with lung cancer in Turkey and it can be safely used in clinical practices.Öğe The assessment of the effect of changes in lung cancer follow-up period to the quality of life by using EQ-5D questionnaire and follow data (the project of AKAYAK-1)(European Respiratory Soc Journals Ltd, 2013) Gursul, Kader Kiyar; Erbaycu, Ahmet Emin; Goksel, Tuncay; Eser, Erhan; Basarik, Burcu; Oz, Aysen; Celik, Pinar; Ediz, Ebru Cakir; Hatipoglu, Osman; Yayla, Bedriye Atay; Baser, Sevin; Baydur, HakanÖğe Breath as the mirror of our body is the answer really blowing in the wind? Recent technologies in exhaled breath analysis systems as non-invasive sensing platforms(Elsevier Sci Ltd, 2021) Beduk, Tutku; Durmus, Ceren; Hanoglu, Simge Balaban; Beduk, Duygu; Salama, Khaled Nabil; Goksel, Tuncay; Turhan, KutsalHealth care monitoring is an enormous field of research that has great potential to solve many problems in human life. In recent years, non-invasive health monitoring has become a prerequisite for early diagnosis of various diseases such as lung cancer, oxidative stress, diabetes, to enable the prompt treatment and screening of crucial chemicals. Although analyzing of exhaled breath has been correlated with advanced analytical techniques such as gas chromatography and infrared spectroscopy, breath analyzing biosensing systems offer a cost-effective, sensitive platform for a straightforward analysis. However, current non-invasive sensing strategies have been lacking in practicality in terms of the design and usage, on-site ability and accessibility. This review will critically discuss current commercialized breath analyzers, the recent achievements for the use of the detection towards chemical and biological substances from exhaled breath as non-invasive sensing systems including challenges/drawbacks by addressing the practical applications and concerns in the field. The different fabrication strategies, methodology of detection techniques involved in the development of the breath analyzing systems will be overviewed and discussed along with the future opportunities for possible point of care applications with smartphone integration in this review. The scientific and technological challenges in the field are discussed in the conclusion. (C) 2021 Elsevier B.V. All rights reserved.Öğe cfDNA in exhaled breath condensate (EBC) and contamination by ambient air: toward volatile biopsies(Iop Publishing Ltd, 2019) Koc, Altug; Goksel, Tuncay; Pelit, Levent; Korba, Korcan; Dizdas, Tugberk N.; Baysal, Ertan; Uzun, Umut C.; Kaya, Ozge Ozer; Ozyilmaz, Berk; Kutbay, Yasar B.; Ozdemir, Taha Resid; Kirbiyik, Ozgur; Erdogan, Kadri M.; Guvenc, Merve Saka; Kocal, Gizem Calibasi; Basbinar, YaseminExhaled breath is a source of volatile and nonvolatile biomarkers in the body that can be accessed non-invasively and used for monitoring. The collection of lung secretions by conventional methods such as bronchoalveolar lavage, induced sputum collection, and core biopsies is limited by the invasive nature of these methods. Non-invasive collection of exhaled breath condensate (EBC) provides fluid samples that are representative of airway lining fluids. Various volatile and nonvolatile biomarkers can be detected in volatile condensates, such as H2O2, nitric oxide, lipid mediators, cytokines, chemokines, DNA, and microRNAs. Studies have examined cell-freeDNA(cfDNA) in plasma samples from non-small-cell lung cancer patients, offering to new insights and fostering development of the liquid biopsy. However, few studies have examined cfDNA in EBC samples. This study examined whether EBC is an appropriate source of cfDNA using housekeeping-gene-specific primer probes and quantitative real-time polymerase chain reaction in healthy subjects. Ambient (room) air is contaminated with DNA, so caution is needed. Preliminary studies indicated that volatile biopsies are becoming an important diagnostic tool in lung cancer.Öğe Clinical Characteristics of Patients with Bronchioloalveolar Carcinoma: A Retrospective Study of 44 Cases(Asian Pacific Organization Cancer Prevention, 2013) Dirican, Nigar; Baysak, Aysegul; Cok, Gursel; Goksel, Tuncay; Aysan, TulinBackground: Bronchioloalveolar carcinoma (BAC) is considered a subtype of adenocarcinoma of the lung. Recently BAC has been variously termed adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant invasive adenocarcinoma, and invasive mucinous adenocarcinoma. The aim of the study was to analyze and detect prognostic factors of patients with BAC over a 7-year period. Materials and Methods: This retrospective single-center study included 44 patients with BAC. The impact on survival of fifteen variables (gender, age, smoking status, cough, dyspnea, hemoptysis, fever, chest pain, sputum, metastasis number, Karnofsky performance status, pT, pN, TNM stage, cytotoxic chemoterapy) were assessed. Results: Median age was 55 years (38-83). Most patients were male (63.6%) and stage IV (59.1%). Twenty-one patients (47.7%) received cytotoxic chemotherapy (platinum-based regimens) for metastatic disease. Objective response rate was 33.3% (4 partial, 3 complete responses). Stable disease was observed in nine in patients (42.8%). Disease progression was noted in 5 (23.8%). The median OS for all patients was 12 months (95% CI, 2.08-22.9 months). Independent predictors for overall survival were: Karnofsky performance status (HR:3.30, p 0.009), pN (HR:3.81, p 0.018), TNM stage (HR:6.49, p 0.012) and hemoptysis (HR:2.31, p 0.046). Conclusions: Karnofsky performance status, pN, TNM stage and hemoptysis appear to have significant impact on predicting patient survival in cases of BAC.Öğe Clinical Characteristics of Patients with Bronchioloalveolar Carcinoma: A Retrospective Study of 44 Cases(Asian Pacific Organization Cancer Prevention, 2013) Dirican, Nigar; Baysak, Aysegul; Cok, Gursel; Goksel, Tuncay; Aysan, TulinBackground: Bronchioloalveolar carcinoma (BAC) is considered a subtype of adenocarcinoma of the lung. Recently BAC has been variously termed adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant invasive adenocarcinoma, and invasive mucinous adenocarcinoma. The aim of the study was to analyze and detect prognostic factors of patients with BAC over a 7-year period. Materials and Methods: This retrospective single-center study included 44 patients with BAC. The impact on survival of fifteen variables (gender, age, smoking status, cough, dyspnea, hemoptysis, fever, chest pain, sputum, metastasis number, Karnofsky performance status, pT, pN, TNM stage, cytotoxic chemoterapy) were assessed. Results: Median age was 55 years (38-83). Most patients were male (63.6%) and stage IV (59.1%). Twenty-one patients (47.7%) received cytotoxic chemotherapy (platinum-based regimens) for metastatic disease. Objective response rate was 33.3% (4 partial, 3 complete responses). Stable disease was observed in nine in patients (42.8%). Disease progression was noted in 5 (23.8%). The median OS for all patients was 12 months (95% CI, 2.08-22.9 months). Independent predictors for overall survival were: Karnofsky performance status (HR:3.30, p 0.009), pN (HR:3.81, p 0.018), TNM stage (HR:6.49, p 0.012) and hemoptysis (HR:2.31, p 0.046). Conclusions: Karnofsky performance status, pN, TNM stage and hemoptysis appear to have significant impact on predicting patient survival in cases of BAC.Öğe The clinical characteristics of sarcoid arthropathy based on a prospective cohort study(Sage Publications Ltd, 2016) Kobak, Senol; Sever, Fidan; Usluer, Ozan; Goksel, Tuncay; Orman, MehmetBackground: Sarcoidosis is known as a Th1-mediated disease, which can mimic many primary rheumatologic diseases or sometimes co-exist with them. Clinical characteristics of sarcoid arthropathy are not well described and the studies reported in the literature so far are mostly based on data from referrals. The aim of this study was to evaluate the incidence and clinical characteristics of sarcoid arthropathy. Methods: All our patients were prospectively evaluated in our rheumatology outpatient center from 2011 to 2015. A total of 114 (32 male) patients with sarcoidosis who were admitted to our clinic were included in the study. Clinical, demographical, laboratory, radiological and histological data of these patients obtained during 4-year follow-up and treatment period were compiled and analyzed. Results: The mean patient age was 48.1 years (range, 20-82 years), and the mean disease duration was 40.5 months (range, 1-300 months). Sarcoid arthritis was observed in 71 (62.3%), and arthralgia in 106 (92.9%) patients. Out of the 71 patients with arthritis, 61 (85.9%) had involvement of ankle, 7 (9.8%) knee, 2 (2.8%) wrist, MCP and PIP joints, and 1 (1.4%) had shoulder periarthritis. Oligoarthritis (two to four joints) was the most common pattern followed by monoarthritis and polyarthritis. Arthritis and erytjhema nodosum and arthritis and female sex was found to be correlated (p = 0.03 and p = 0.001). Again, in patients with arthritis, even higher levels of CRP/ESR as well as ANA and RF positivity were observed (p = 0.03, p = 0.01, p = 0.01, and p = 0.02, respectively). A total of 11 patients had another rheumatic pathology concurrent with sarcoidosis. Conclusions: Inflammatory arthritis occurs in a majority of patients with sarcoidosis. Acute arthritis with bilateral ankle involvement is the most common pattern of sarcoid arthropathy. Sarcoidosis can mimic many primary rheumatic diseases or may coexist with them. Sarcoidosis should be considered not only as a mimicker but also as a Th1-mediated primary rheumatologic pathology.Öğe Comparison of different generic and lung cancer specific quality of life instruments for their predictive ability of survival in patients with advanced lung cancer(Springer, 2014) Eser, Sultan; Goksel, Tuncay; Erbaycu, Ahmet Emin; Eser, Erhan; Basarik, Burcu; Oz, Aysen; Gursul, Kader Kiyar; Celik, Pinar; Ediz, Ebru Cakir; Hatipoglu, Osman; Atay, Bedriye; Baser, Sevin; Baydur, HakanÖğe Comparison of generic and lung cancer-specific quality of life instruments for predictive ability of survival in patients with advanced lung cancer(Springer International Publishing Ag, 2016) Eser, Sultan; Goksel, Tuncay; Erbaycu, Ahmet Emin; Baydur, Hakan; Basarik, Burcu; Yanik, Aysen Oz; Gursul, Kader Kiyar; Celik, Pinar; Ediz, Ebru Cakir; Hatipoglu, Osman; Yayla, Bedriye Atay; Baser, Sevin; Eser, ErhanBackground: Our purpose is to examine the relationship of Health related quality of life measured by EORTC QLQc30, QLQ-LC13; FACT-L, LCSS, Eq5D) with survival in advanced lung cancer patients. A total of 299 Lung Cancer (LC) patients were, included in this national multicenter Project entitled of "the LC Quality of Life Project (AKAYAK). Baseline scores were analyzed by using Cox's proportional hazard regression to identify factors that influenced survival. Univariate and multivariate models were run for each of the scales included in the study. Results: Mean and median survival were 12.5 and 8.0 months respectively. Clinical stage (as TNM), comorbidity; symptom scales of fatigue, insomnia, appetit loss and constipation were associated with survival after adjustment for age and sex. Global, physical and role functioning scales of QLQc30; physical and functional scales of LCS and TOI of the FACT-L was also associated with survival. Mobility and Usual activities dimensions of the Eq5D; Physical functioning and the constipation symptom scale of the QLQ-c30; and LCS and TOI scores of the FACT-L remained statistically significant after adjustment. LC13 and LCSS scales were not predictors of survival. Conclusions: HRQOL serves as an additional predictive factor for survival that supplements traditional clinical factors. Besides the strong predictive ability of ECOG on survival, FACT-L and the Eq5D are the most promising HRQOL instruments for this purpose.Öğe * Concordance in molecular genetic analysis of tumour tissue, plasma, and exhaled breath condensate samples from lung cancer patients(Iop Publishing Ltd, 2020) Vardarli, Asli Tetik; Pelit, Levent; Aldag, Ceyda; Korba, Korcan; Celebi, Caglar; Dizdas, Tugberk Nail; Goksel, TuncayAim. Lung adenocarcinoma is characterized by poor prognosis and short survival rates. Therefore, tools to identify the tumoural molecular structure and guide effective diagnosis and therapy decisions are essential. Surgical biopsies are highly invasive and not conducive for patient follow-up. To better understand disease prognosis, novel non-invasive analytic methods are needed. the aim of the present study is to identify the genetic mutations in formalin-fixed paraffin-embedded (FFPE) tissue, plasma, and exhaled breath condensate (EBC) samples by next-generation sequencing and evaluate their utility in the diagnosis and follow-up of patients with lung adenocarcinoma. Method. FFPE, plasma, and EBC samples were collected from 12 lung adenocarcinoma patients before treatment. DNA was extracted from the specimens using an Invitrogen PureLink Genomic DNA Kit according to the manufacturer's instructions. Amplicon-based sequencing was performed using Ion AmpliSeq Colon and Lung Cancer Research Panel v2. Results. Genetic alterations were detected in all FFPE, plasma, and EBC specimens. the mutations in PIK3CA, MET, PTEN, SMAD4, and FGFR2 genes were highly correlated in six patients. Somatic and novel mutations detected in tissue and EBC samples were highly correlated in one additional patient. the EGFR p.L858R and KRAS p.G12C driver mutations were found in both the FFPE tissue specimens and the corresponding EBC samples of the lung adenocarcinoma patients. Conclusion. the driver mutations were detected in EBC samples from lung adenocarcinoma patients. the analysis of EBC samples represents a promising non-invasive method to detect mutations in lung cancer and guide diagnosis and follow-up.Öğe Conversion of specific lncRNAs to biomarkers in exhaled breath condensate samples of patients with advanced stage non-small-cell lung cancer(Frontiers Media Sa, 2023) Vardarli, Asli Tetik; Ozgur, Su; Goksel, Tuncay; Korba, Korcan; Karakus, Hardar Soydaner; Asik, Aycan; Pelit, LeventObjectives: Lung cancer (LC) is one of the most prevalent cancers with the highest fatality rate worldwide. Long noncoding RNAs (lncRNAs) are being considered potential new molecular targets for early diagnosis, follow-up, and individual treatment decisions in LC. Therefore, this study evaluated whether lncRNA expression levels obtained from exhaled breath condensate (EBC) samples play a role in the occurrence of metastasis in the diagnosis and follow-up of patients with advanced lung adenocarcinoma (LA).Methods: A total of 40 patients with advanced primary LA and 20 healthy controls participated in the study. EBC samples were collected from patients (during diagnosis and follow-up) and healthy individuals for molecular analysis. Liquid biopsy samples were also randomly obtained from 10 patients with LA and 10 healthy people. The expression of lncRNA genes, such as MALAT1, HOTAIR, PVT1, NEAT1, ANRIL, and SPRY4-IT1 was analyzed using cfRNA extracted from all clinical samples.Results: In the diagnosis and follow-up of patients with LA, lncRNA HOTAIR (5-fold), PVT1 (7.9-fold), and NEAT1 (12.8-fold), PVT1 (6.8-fold), MALAT1 (8.4-fold) expression levels were significantly higher than those in healthy controls, respectively. Additionally, the distinct lncRNA expression profiles identified in EBC samples imply that decreased ANRIL-NEAT1 and increased ANRIL gene expression levels can be used as biomarkers to predict the development of bone and lung metastases, respectively.Conclusion: EBC is an innovative, easily reproducible approach for predicting the development of metastases, molecular diagnosis, and follow-up of LC. EBC has shown potential in elucidating the molecular structure of LC, monitoring changes, and discovering novel biomarkers.Öğe Design of Polymeric Surfaces as Platforms for Streamlined Cancer Diagnostics in Liquid Biopsies(MDPI, 2023) Ghorbanizamani, Faezeh; Moulahoum, Hichem; Celik, Emine Guler; Zihnioglu, Figen; Beduk, Tutku; Goksel, Tuncay; Turhan, KutsalMinimally invasive approaches for cancer diagnosis are an integral step in the quest to improve cancer survival. Liquid biopsies such as blood samples are matrices explored to extract valuable information about the tumor and its state through various indicators, such as proteins, peptides, tumor DNA, or circulating tumor cells. Although these markers are scarce, making their isolation and detection in complex matrices challenging, the development in polymer chemistry producing interesting structures, including molecularly imprinted polymers, branched polymers, nanopolymer composites, and hybrids, allowed the development of enhanced platforms with impressive performance for liquid biopsies analysis. This review describes the latest advances and developments in polymer synthesis and their application for minimally invasive cancer diagnosis. The polymer structures improve the operational performances of biosensors through various processes, such as increased affinity for enhanced sensitivity, improved binding, and avoidance of non-specific interactions for enhanced specificity. Furthermore, polymer-based materials can be a tremendous help in signal amplification of usually low-concentrated targets in the sample. The pros and cons of these materials, how the synthesis process affects their performance, and the device applications for liquid biopsies diagnosis will be critically reviewed to show the essentiality of this technology in oncology and clinical biomedicine.Öğe Diagnostic Yield of Bronchoscopy with C-Arm Scopy in Cases without Endobronchial Lesion(Derman Medical Publ, 2016) Emre, Julide Celdir; Baysak, Aysegul; Oz, Adnan Tolga; Cok, Gursel; Goksel, TuncayAim: Fiberoptic bronchoscopy (FOB) is widely used in the diagnosis and treatment of pulmonary diseases. FOB sensitivity is generally low in tumors localized in the outer third of the lung. Diagnosis of peripheral pulmonary lesions can be difficult; however, the use of computed tomography (CT)-, fluoroscopy- or ultrasonography (USG)-guided surgery increases the diagnostic rates. In this study we aimed to compare the diagnostic values of C-arm fluoroscopy-guided bronchoscopic lavage, brushing, and biopsy samples obtained in cases where radiological masses or parenchymal lesions were detected, but endobronchial pathology was not found. Material and Method: In this prospective observational study, bronchoscopy was performed to the patients who had a mass lesion or parenchymal infiltration on chest radiogram and who had no endobronchial lesion, the diagnostic results of the bronchoscopic lavage, brush and biopsy specimens have been compared where C-arm scopy guided the procedures. Results: 60 patients (45 male) with a mean age 61.5 +/- 9.6 were enrolled into the study. The lesions were mostly located in the right upper lobe. 45 patients had peripheral mass lesion, 17 patients had noduler lesion where consolidation or infiltration were present in 18 patients. The diagnostic yield of the bronchoscopic biopsy was 36%, brushing 20% and 21% for the bronchoscopic lavage. Overall diagnostic yield with all bronchoscopic methods was 45%. In lesions with a diameter of <3 cm, bronchoscopic brushing was significantly ineffective. There was not any severe complication due to these procedures. Discussion: The C-arm scopy guided bronchoscopic biopsy was much more valuable in the diagnosis of peripheral lesions.Öğe A drug-responsive multicellular human spheroid model to recapitulate drug-induced pulmonary fibrosis(Iop Publishing Ltd, 2022) Saygili, Ecem; Devamoglu, Utku; Goker-Bagca, Bakiye; Goksel, Ozlem; Biray-Avci, Cigir; Goksel, Tuncay; Yesil-Celiktas, OzlemAssociated with a high mortality rate, pulmonary fibrosis (PF) is the end stage of several interstitial lung diseases. Although many factors are linked to PF progression, initiation of the fibrotic process remains to be studied. Current research focused on generating new strategies to gain a better understanding of the underlying disease mechanism as the animal models remain insufficient to reflect human physiology. Herein, to account complex cellular interactions within the fibrotic tissue, a multicellular spheroid model where human bronchial epithelial cells incorporated with human lung fibroblasts was generated and treated with bleomycin (BLM) to emulate drug-induced PF. Recapitulating the epithelial-interstitial microenvironment, the findings successfully reflected the PF disease, where excessive alpha smooth muscle actin and collagen type I secretion were noted along with the morphological changes in response to BLM. Moreover, increased levels of fibrotic linked COL13A1, MMP2, WNT3 and decreased expression level of CDH1 provide evidence for the model reliability on fibrosis modelling. Subsequent administration of the Food and Drug Administration approved nintedanib and pirfenidone anti-fibrotic drugs proved the drug-responsiveness of the model.Öğe The effect of changes in quality of life in patients with lung cancer in the observation period (European Organization for Research and treatment of Cancer) EORTC QLQ-C 30 results of the evaluation and follow-up (AKAYAK-1 project)(European Respiratory Soc Journals Ltd, 2013) Oz, Aysen; Celik, Pinar; Goksel, Tuncay; Erbaycu, Ahmet Emin; Eser, Erhan; Basarik, Burcu; Gursul, Kader Kiyar; Ediz, Ebru Cakir; Hatipoglu, Osman; Yayla, Bedriye Atay; Baser, Sevin; Baydur, Hakan
- «
- 1 (current)
- 2
- 3
- »
